[go: up one dir, main page]

WO2024107577A3 - Immune checkpoint multivalent particles compositions and methods of use - Google Patents

Immune checkpoint multivalent particles compositions and methods of use Download PDF

Info

Publication number
WO2024107577A3
WO2024107577A3 PCT/US2023/079138 US2023079138W WO2024107577A3 WO 2024107577 A3 WO2024107577 A3 WO 2024107577A3 US 2023079138 W US2023079138 W US 2023079138W WO 2024107577 A3 WO2024107577 A3 WO 2024107577A3
Authority
WO
WIPO (PCT)
Prior art keywords
immune checkpoint
methods
particles compositions
multivalent
multivalent particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/079138
Other languages
French (fr)
Other versions
WO2024107577A2 (en
Inventor
Chang-Zheng Chen
Hua Zhou
Michael Chen
Tian-Qiang Sun
Michael Lincoln
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Achelois Biopharma Inc
Original Assignee
Achelois Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achelois Biopharma Inc filed Critical Achelois Biopharma Inc
Priority to EP23892320.5A priority Critical patent/EP4619424A2/en
Priority to CN202380091370.8A priority patent/CN121057753A/en
Publication of WO2024107577A2 publication Critical patent/WO2024107577A2/en
Publication of WO2024107577A3 publication Critical patent/WO2024107577A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Provided herein are multivalent particles and compositions of multivalent particles expressing immune checkpoint molecules.
PCT/US2023/079138 2022-11-14 2023-11-08 Immune checkpoint multivalent particles compositions and methods of use Ceased WO2024107577A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP23892320.5A EP4619424A2 (en) 2022-11-14 2023-11-08 Immune checkpoint multivalent particles compositions and methods of use
CN202380091370.8A CN121057753A (en) 2022-11-14 2023-11-08 Immune checkpoint multivalent particle compositions and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263425157P 2022-11-14 2022-11-14
US63/425,157 2022-11-14

Publications (2)

Publication Number Publication Date
WO2024107577A2 WO2024107577A2 (en) 2024-05-23
WO2024107577A3 true WO2024107577A3 (en) 2024-09-26

Family

ID=91085307

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/079138 Ceased WO2024107577A2 (en) 2022-11-14 2023-11-08 Immune checkpoint multivalent particles compositions and methods of use

Country Status (3)

Country Link
EP (1) EP4619424A2 (en)
CN (1) CN121057753A (en)
WO (1) WO2024107577A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190010207A1 (en) * 2015-06-19 2019-01-10 Sebastian Kobold Pd-1-cd28 fusion proteins and their use in medicine
US20200339654A1 (en) * 2019-04-29 2020-10-29 Mayo Foundation For Medical Education And Research Multivalent pd-l1 binding compounds for treating cancer
US20220332769A1 (en) * 2020-10-30 2022-10-20 Achelois Biopharma, Inc. Multivalent particles compositions and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190010207A1 (en) * 2015-06-19 2019-01-10 Sebastian Kobold Pd-1-cd28 fusion proteins and their use in medicine
US20200339654A1 (en) * 2019-04-29 2020-10-29 Mayo Foundation For Medical Education And Research Multivalent pd-l1 binding compounds for treating cancer
US20220332769A1 (en) * 2020-10-30 2022-10-20 Achelois Biopharma, Inc. Multivalent particles compositions and methods of use

Also Published As

Publication number Publication date
CN121057753A (en) 2025-12-02
WO2024107577A2 (en) 2024-05-23
EP4619424A2 (en) 2025-09-24

Similar Documents

Publication Publication Date Title
WO2022246053A3 (en) Immune checkpoint multivalent particles compositions and methods of use
EP4021498A4 (en) Cross-species anti-latent tgf-beta 1 antibodies and methods of use
AU2022262421A1 (en) Anti-tslp antibody compositions and uses thereof
WO2023201299A8 (en) Pharmaceutical compositions of therapeutic proteins and methods of use
WO2024107577A3 (en) Immune checkpoint multivalent particles compositions and methods of use
CA3261512A1 (en) Anti-gpnmb antibodies and methods of use thereof
CA3248984A1 (en) Anti-alk1 antibodies and methods of using the same
HK40112898A (en) Anti-alk1 antibodies and methods of using the same
HK40064823A (en) Anti-claudin 18 antibodies and methods of use thereof
HK40117802A (en) Modified immune cells and methods of using the same
HK40122448A (en) Cross-species anti-latent tgf-beta 1 antibodies and methods of use
HK40123103A (en) Cross-species anti-latent tgf-beta 1 antibodies and methods of use
TW202545564A (en) Pharmaceutical compositions of therapeutic proteins and methods of use
HK40079672A (en) Formulations of human anti-tslp antibodies and methods of using the same
HK40122875A (en) Anti-tigit antibodies and uses of the same
HK40110732A (en) Anti-sirp-alpha antibodies and methods of use thereof
HK40093044A (en) Anti-tmem106b antibodies and methods of use thereof
HK40102880A (en) Surface modified red blood cells and methods of generating the same
CA3280499A1 (en) Anti-cdh17 antibodies and use of the same
CA3281330A1 (en) Anti-latent tgf-beta 1 antibodies and methods of use
HK40114065A (en) Il1rap antibodies and uses thereof
HK40120806A (en) Anti-cd137 antibodies and methods of making and using the same
HK40108519A (en) Anti-siglec-6 antibodies and methods of use thereof
HK40113185A (en) Pilra antibodies and methods of use thereof
HK40111190A (en) Anti-sirp-alpha antibodies and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23892320

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2023892320

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023892320

Country of ref document: EP

Effective date: 20250616

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23892320

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2023892320

Country of ref document: EP